Animal and Veterinary Sciences
2022; 10(5): 131-147
http://www.sciencepublishinggroup.com/j/avs
doi: 10.11648/j.avs.20221005.13
ISSN: 2328-5842 (Print); ISSN: 2328-5850 (Online)

Review of the Diagnostic Method, the Importance of Public Health, and Current Status of Brucellosis in Small Ruminants in Ethiopia

Teferi Benti Moti

Department of Microbiology, Animal Health Institute, Sebeta, Ethiopia

Email address:
teferibenti58@gmail.com

To cite this article:
Teferi Benti Moti. Review of the Diagnostic Method, the Importance of Public Health, and Current Status of Brucellosis in Small Ruminants in Ethiopia. *Animal and Veterinary Sciences*. Vol. 10, No. 5, 2022, pp. 131-147. doi: 10.11648/j.avs.20221005.13

Received: July 29, 2022; **Accepted**: September 15, 2022; **Published**: October 17, 2022

Abstract: Brucellosis is a zoonotic bacterial disease caused by several species in the genus *Brucella*. Reproductive losses are the most common syndrome in animals, while people may suffer from a debilitating nonspecific illness or localized involvement of various organs. Each species of *Brucella* tends to be associated with a specific animal host, but other species can be infected, especially when they are kept in close contact. Sheep and goats are the usual hosts for *Brucella melitensis,* and *B. ovis* primarily infects sheep. However, this organism is also reported to be common in camels and cattle in some regions with extensive small ruminant populations. *B. melitensis* is the most dangerous to humans. Small ruminants often acquire *B. melitensis* by coming into contact with organisms in vaginal discharges and birth products (placenta, fetus, and fetal fluids). Most animals are thought to become infected by ingestion and through the oronasal and conjunctival mucosa, but this organism can also be transmitted venereally and through broken skin. The genus Brucella is a non-spore-forming, facultative intracellular, non-encapsulating, gram-negative coccobacillus. Humans usually become infected by ingesting organisms or via contaminated mucous membranes (including the conjunctiva and respiratory tract) and abraded skin, consumption of unpasteurized milk and by-products, and improper handling of disposable materials. The predominant clinical signs in sheep and goats are abortions (most often during the last trimester), stillbirths, and the birth of weak offspring. *Brucella ovis*, which mostly affects rams and causes epididymitis and orchitis, appears to be non-pathogenic for humans. Brucellosis hinders the live animal trade and animal products internationally. Laboratorial examinations of brucellosis can be done by serological, cultural, or molecular methods. An accurate diagnosis, the culling of diseased animals and ongoing observation of herds that are brucellosis-free are necessary for the control of the disease in animals. The purpose of the review was to provide information on sheep and goat brucellosis in Ethiopia, diagnostic methods, and the importance of public health, control, and prevention concerns.

Keywords: Brucellosis, *Brucella Melitensis*, *Brucella Ovis*, Humans, Small Ruminants, Zoonosis

1. Introduction

Small ruminants, which account for about half of all domesticated ruminants in the world, are a crucial part of the farming system [1]. The small ruminant population in the world is estimated to range from 1.35 billion to 1.94 billion [2]. Small ruminants play an important role in livestock husbandry, particularly where livestock is kept for immediate cash, milk, meat, wool, and saving. In tropical and subtropical Africa, small ruminants provide a range of social and cultural activities that vary among different cultures, Socio-economies, and agro-ecologies [3]. Various Smallholder farmers prefer sheep and goats to large ruminants for various reasons, including reduced feed costs, faster returns, easy management, and acceptable slaughter [4].

According to the Central Statistical Agency [5], Ethiopia has the largest animal population in Africa, with 65 million cattle, 51 million goats, 40 million sheep, 8 million camels, and 49 million chickens; donkeys, 8.44 million, horses, 2.16 million, and mules, 0.41 million [6]. Lowland areas are home to 73% of the country's goats and 25% of its sheep [7]. Sheep and goats are the most important sources of cash income for

rural women [8]. There are three predominant management systems in the country: mixed crop-livestock, intensive management, and pastoral/agro-pastoral (extensive). At community grazing fields and watering stations, the country's customary extended husbandry practices yield plenty of blending of different animal species [9].

The livestock production system is predominantly extensive, with indigenous breeds and low-input/low-output husbandry practices. The productivity of this sector is constrained by several factors. This can be due to underfeeding, poor management, low reproductive performance, feed availability during drought season, disease incidence, parasitic diseases, poor genetics, and low accessibility to services and inputs [10, 11]. In line with the Food and Agriculture Organization and also the World Health Organization, Brucellosis is one of the zoonotic diseases that have spread among small ruminants [12-14]. Similarly, the Office International des Epizooties (OIE) indicates brucellosis is an infection and infestation that affects a variety of animal species [15].

Brucella species are harmful bacteria that have an inclination to adapt to new hosts. They'll spread naturally to their original hosts through direct or indirect contact, or they'll spread to new vulnerable hosts inadvertently [16]. The danger of brucellosis has increased because of mixed farming with small ruminants functioning as primary hosts and cattle serving as spillover hosts for *B. melitensis* [17]. Brucellosis affects farm animals, wild animals, and marine mammals everywhere on the globe and may be a public-health threat. It's a disease of the reproductive system, causing inflammation of the reproductive organs and embryonic membranes, causing abortion, infertility, and infection. Invading Brucellae, usually localized in the lymph nodes, results in local infection and the escape of Brucella from the lymph nodes into the blood [14, 18]. Goats and sheep are the primary hosts for *B. melitensis* and *B. ovis*, respectively [18, 19]. Brucellosis has an effect on the livestock industry market because it reduces breeding efficiency, meat and milk yield. Furthermore, the disease may be a significant impediment to international trade in animals and animal products [20].

Brucellosis could be a zoonotic disease that affects humans, with an estimated half-million human cases reported every year [21]. The disease is transmitted to people through direct contact with infected animals and their tissues or fluid discharges. Most routes of transmission to humans are through the ingestion of raw milk or unpasteurized dairy products [16]. As a result, the review's goal was to collect the most current knowledge on small ruminant Brucellosis, including its public health impact, etiology, diagnostic tests, control, and prevention.

2. Literature Review

2.1. Etiology of Brucellosis in Small Ruminants

Brucella melitensis is the common cause of brucellosis in sheep and goats. It belongs to the Brucellaceae family, Rhizobiales order, and Alphaproteobacteria class [15]. Bruce discovered the causative bacterium from the liver of a patient who died of an infectious disease (Malta fever) in 1870 [22, 23]. The taxonomic factors that are likely to separate the genus into numerous species are physiological variations, phage susceptibility, host preference, and cell envelope structural traits as rough and smooth [24]. In sheep and goats, infection is caused by *B. Melitensis* is pathologically and epidemiologically similar to B. abortus in cattle and primarily pigs infected by B. susi but it has also been found in sheep and goats [15]. It predominantly affects animals' reproductive tracts, but it also offers a significant health risk to humans [25, 26].

The most common Brucella species are Brucella abortus, Brucella suis, *Brucella melitensis*, *Brucella ovis*, Brucella canis, Brucella neotomae, Brucella ceti, Brucella microti, Brucella pinnipedialis, Brucella inopinata, Brucella papionis, Brucella vulpis, and other strains without standing in nomenclature that include environmental samples [27, 28, 29]. B. ceti and B. pinnipedialis were recovered from marine creatures; while B. inopinata (found in a very human body) and B. microti were isolated from the common vole [30-32]. Cross-infection between species does occur, however, through ingestion, inhalation, and direct contact, which are the main routes of infection in both animals and humans [33]. Brucellosis in cattle is caused by B. abortus, which has eight biovars; brucellosis in pigs is caused by B. suis, which has five biovars; brucellosis in sheep and goats is caused by *B. melitensis*, which has three biovars; *B. ovis* affects rams, and B. canis affects dogs [18, 34].

The most common causes of brucellosis in small ruminants are *B. melitensis* and *B. ovis*; however, B. abortus and B. suis have been reported in small ruminants, indicating the possibility of transmission from one species to another [30, 35]. Goat breeds are more susceptible to *B. melitensis* and vary in sheep breeds. *B. ovis* primarily affects sheep [36] and may be an explanation for orchitis and epididymitis in rams, although ewes can also be infected [37]. The most pathogenic species for humans are *B. melitensis*, B. suis, and B. abortus [38], and B. canis incorporates a modest zoonotic potential [39]. Some Brucella species are nonpathogenic to humans, like B. neotomae, B. microti, and *B. ovis* [40].

Table 1. *Brucella Species and their Host Preference.*

Species	Zoonotic importance	Host preference
B. melitensis	High	Sheep, Goat
B. abortus	Moderate	Cattle
B. suis	Moderate	Pig
B. canis	Mild	Dog
B. ovis	Absent	Sheep
B. neotome	Absent	Deseret wood rat (*Neotomelepida*)
B. ceti	Mild	Ceteceans
B. Pinnipedials	Mild	Seals
B. microt	Absent	Common Voles (M*icrotusarvalis*)
B. inopinata	Mild	Undetermined host

Source: [43].

Brucella melitensis causes abortion, weak offspring or stillbirth, placental retention in females, and acute epididymitis and orchitis in rams, which results in infertility in both and economic losses [41, 42], Brucella species are a host preference, as evidenced by their ability to determine chronic infection in people as well as maintain transmission and infection in groups of specific animal species [43]. Based on their outer composition, Brucella can be as smooth (S) or rough (R) and express an entire LPS molecule (S-LPS) that's anchored within the outer membrane. The presence of S-LPS appears to be associated with virulence. The commonly identified human pathogens *B. melitensis*, B. abortus, and B. suis are "smooth" because S-LPS is present in their outer membrane. The remaining species (B. canis, *B. ovis*, and B. neotomae) are characterized as rough strains, providing they express little or no S-LPS and cause less severe or no disease in humans [44].

2.2. Morphology

Brucellae are intracellular coccobacilli or short rods 0.6 to 1.5 m long by 0.5 to 0.7 μm wide, usually arranged singly; they rarely form pairs [34]. Brucella organisms require CO_2 for their growth, especially B. abortus; such organisms are called capnophilic organisms. Brucella doesn't have the potential to survive at pH levels less than four [45]. Brucella is fairly constant in morphology except in old cultures, where pleomorphic forms may occur. Brucella could be a non-spore-forming, non-motile, non-encapsulated, facultative intracellular and gram-negative coccobacilli (or short rod) bacterium that doesn't usually show bipolar staining [46]. They are not truly acid-fast but resist depolarization by weak acids. Stamp's modification of the Ziehl-Neelsen stained red is usually used for the microscopic diagnosis of brucellosis from smears of solid or liquid specimens [47].

2.3. Epidemiology

2.3.1. Geographical Distribution

Brucellosis could also be a highly contagious bacterial disease affecting both animals and humans [48]. The Middle East, Central and Southeast Asia, Sub-Saharan Africa, and parts of Latin America continue to be the most affected by Brucellosis [49, 50]. This organism is absent from domesticated animals in northern and central Europe, Canada, the U.S., Australia, New Zealand, Japan, and some other countries, but sporadic cases are occasionally reported in travelers and immigrants [15]. Brucellosis is endemic in Africa, particularly in North Africa, where sanitary data is available, whereas in most African countries, fragmentary clinical data collection does not provide a reliable prevalence status [38].

Brucella melitensis should be taken into account as a re-emerging pathogen [51]. Large numbers of bacteria are shed within the birth fluids or fetus, placenta, and abortion secretions of infected females. The bacteria can survive for several months outdoors, especially in cold, wet conditions, where they are still infectious to other animals, mainly through ingestion and colonizing the udder and contaminating milk [52]. Sexually matured animals have a greater susceptibility to brucellosis than young animals; although it's possible for young animals to be latently infected, and these animals may eventually become a source of infection when mature [13].

Among Brucella spp., *Brucella melitensis* is the most virulent, with biovars 1 and 3 being those isolated most frequently in small ruminants within the Mediterranean, the Middle East, and Latin America. Brucellosis can be a barrier to live animal trade and animal products. Brucellosis is of major economic importance in most countries of the world, and it affects approximately 50% of the livestock population worldwide and continues to increase in distribution [53].

Goats are the classic and natural hosts of *B. melitensis* and, together with sheep, are its preferred host. In pathological and epidemiological terms, *B. melitensis* infection in small ruminants is similar to *B. abortus* infection in cattle. The main clinical manifestations of brucellosis in ruminants are abortions and stillbirths, which usually occur in the last third of the pregnancy following infection, and usually only once in the animal's lifetime [54]. Among the members of the *Brucella* group B. abortus, *B. melitensis*, and B. suis species don't seem to be host-specific. From epidemiological evidence, the three species cause infection in an exceedingly wide range of animals, including humans. Cross transmission of brucellosis can occur among cattle, goats, swine, sheep, and other species, including horses, dogs, feral swine, bison, reindeer, and camels [51].

The distribution of human brucellosis has changed over the last fifty years because of various factors like sanitary, socioeconomic, and political conditions, together with the increase in international travel and population migration [55]. The absence of human vaccines will still be a global health threat. The human brucellosis vaccine remains challenging due to the danger of the Brucella organism as a possible bioweapon agent. It's a high risk for human health problems, affecting a minimum of a half-million people annually [56]. *B. melitensis* is the most widespread Brucella spp. infecting humans, and there is no vaccine provided to the current point [57, 58].

2.3.2. Status of Small Ruminant Brucellosis in Ethiopia

Ethiopia's livestock development is hampered by both technological and institutional constraints. Poor links between technological sources like research centers and end users, as well as inadequate extension and financial services, are all limiting institutional issues [59]. Inadequate and low-quality nutrition, extensive disease prevalence, and poor genetic makeup of the animals are among the technical problems, owing partially to a lack of superior breeds or their prohibitive prices [11].

Ethiopia has reported cases of brucellosis in both humans and animals from a number of agro-ecological and pastoral systems. Investigations on animal prevalence were restricted to serological surveys and mostly focused on bovine brucellosis, with sporadic studies on goats, sheep, and camels. According

to a meta-analysis, seroprevalence was highest in Southern Ethiopia (8 percent on average (4.0–12.0 percent), followed by Northern Ethiopia (3 percent on average (1.0–7.0 percent), Eastern Ethiopia (1% on average (1.0–3.0 percent), and the lowest in Central Ethiopia 0.0–3.0 percent [60].

In Ethiopia, the economic impact of brucellosis on livestock production is unknown. However, some researchers have revealed a connection between seropositivity and a history of spontaneous miscarriage in animals. A lack of veterinary infrastructure, poor veterinary research, and a lack of community awareness creation and zoonotic relations all contributed to the knowledge gap regarding the disease's state. According to the sero-surveillance study, one of the most prevalent infections among goats and sheep producers may be brucellosis (Table 2). While [61] reported a high prevalence rate of 17.36 percent in small ruminants in the Borena zone of the Pastoral Area, [10] reported a low prevalence rate of 0.7 percent in and around Kombolcha, Amhara Regional State.

The Bruce-ladder multiplex PCR technique was used to identify four isolates of *B. melitensis*, from three vaginal swabs and one from milk samples, during a genetic investigation in the Amibara district of the Afar Regional State, Ethiopia [62]. Similar to this, only two out of 14 cultivated plates showed bacterial growth, indicating that the two isolates were positive for *B. melitensis* by PCR, from tissue samples taken from 14 goats that were positive for the RBPT [63].

Table 2. *CFT and ELISA based Brucellosis seroprevalence reports on Small Ruminant in different location in Ethiopia.*

S/n	Study area	Region	Prevalence %	References
1	Tellalak District	Afar	13.7	[64]
2	Chifra and Ewa Districts	Afar	12.35	[65]
3	Yabello and Dire district	Oromia	8.8	[66]
4	Pastoral and Agro-pastoral Lowlands	Somali and Oromia	3.3	[63]
5	Borena	Oromia	3.2	[67]
6	Dire Dawa Administrative Council	Dire Dawa	2.6	[68]
7	Hamer & Bena tsemay	SNNP	1.98	[69]
8	Tselemti	Tigray	**1.7**	[21]
9	Three districts of Jijiga Zone	Somali	1.37	[70]
10	Kombolcha & surrounding area	Amhara	0.7	[10]
11	Borena Pastoral area	Oromia	17.36	[61]
12	Borena and Somali Pastoral area	Oromia and Somali	12.84	[71]
13	West Hararghe	Oromia	0.24	[72]
14	East Hararghe	Oromia	0.8	[73]
15.	Bale (dallo-manna)	Oromia	2.9	[74]
16.	Jimma zone	Oromia	4.7	[75]

2.3.3. Source of Infection and Mode of Transmission

Transmission of *B. melitensis* between animals occurs mainly by environmental contamination after abortions or by direct contact. Sexual transmission is also a main route of infection, probably more so in small ruminants than in cattle. Animal owners are more at risk of commingling small ruminants from different herds than they will do with cattle, which promote the transmission of the disease. Dogs can acquire infection with Brucella species; including *B. melitensis*, by ingesting placental material and aborted fetuses, and then infect humans and domestic livestock. *B. melitensis* and *B. ovis* are found mainly in small ruminants, but *B. melitensis* also infects other animal species [13].

The disease is responsible for considerable economic losses to the small-ruminant industry and is a serious zoonotic disease around the globe [76, 77]. Materials excreted from the female genital tract are the greatest supply of organisms for transmission to other animals and humans. The infected animal, after abortion or full-term parturition, disseminates Brucella organisms through the placenta and fetal fluids/discharge within which large numbers of organisms are shed [76].

Horizontal infection occurs through udder contamination during skin penetration, milking, ingestion of contaminated feed, inhalation via conjunctiva, and licking the discharge of a newborn calf, or retained membrane [78]. The importance of venereal transmission varies with the species; it's the primary route of transmission for *B. ovis*, B. suis, and B. canis, but for B. abortus and *B. melitensis* it's not common [79]. The degree of infection in milk and uterine exudates is much lower in sheep. Studies indicate that 70–90% of Brucella infection occurs via the skin and membrane by direct contact [80]. Sheep and goats may remain infected for years, and reinvasion of the uterus can occur during subsequent pregnancies. Shedding within the vaginal discharges of goats could even be persistent, lifelong for 2-3 months, and maybe elongated. *B. melitensis* is additionally shed in milk, urine, and semen [15].

Vertical transmission: *B. melitensis* is transmitted from the dams to lambs or kids in utero, but the bulk of infections are probably acquired by consumption of colostrum or milk. These lambs may have infections within the lymph nodes draining the digestive tube and may excrete Brucella organisms. It’s also probable that a self-cure mechanism is in most of the infected lambs and the survival of latent infections importantly increases. Lambs and kids remain fully susceptible after they reach sexual maturity. The problem of eradicating this disease persists without having a detectable immune response because of immunotolerance. The precise mechanism by which latent *B. melitensis*

infections occur is unknown [81].

Small ruminants are infected after they're young and sometimes become persistent carriers. They'll remain undetectable by diagnostic tests, including serology, until they give birth or abort. A small percentage of these animals could also be born infected, but most are thought to accumulate *B. melitensis* after they nurse from an infected dam. *B. melitensis* is additionally detected in blood-sucking arthropods like ticks, and B. abortus has been transmitted to guinea pigs via tick bites within the laboratory. Trans-ovarian transmission of *B. melitensis* was reported in ticks [15].

Transmission to humans is through direct contact with infected animal carcasses, consumption of unpasteurized milk and animal products, aborted fetuses, and placentas. It's common to find human cases that involve goats during a section where a vigorous brucellosis outbreak occurs. Infected animals, contaminated raw vegetables and water can even be a source of infection. Human infections may occur through breaks within the skin when handling infected animal tissues [56]. In the laboratory and possibly in abattoirs, Brucella is additionally transmitted through aerosols, contact with laboratory cultures and tissue samples, and accidental injection of live Brucella vaccines [82].



Figure 1. *Shows Mode of transmission of Brucella to humans. Source: [83].*

Risk Factors: Brucellosis is predominantly an occupational disease of those working with infected animals or their tissues, but can also infect consumers of unpasteurized dairy products and hunters who unknowingly handle infected animals. Illness in people can be very protracted and painful, and can result in an inability to work and a loss of income. Travelers to areas with enzootic diseases who consume local delicacies, such as goat, sheep, or camel milk or cheese, may become infected [84]. Host factors (intrinsic) are breed, agent, sex and age [85]. Furthermore, as environmental factors like management and ecology are related to brucellosis [86], it's widely accepted that susceptibility increases with sexual development and pregnancy [87]. Kids and lambs may become infected before or soon after birth and have a tendency to become free from infection before reaching breeding age. Infection, on the other hand, can sometimes last much longer [85]. *Brucella melitensis* infection causes disease in sexually mature females and males. Young animals are infected but don't show any clinical signs and regularly show only a weak and transient serological response [88].

Breeding of ewes with infected rams rarely causes the disease in ewes, and abortion rates are low [85]. Animals of exotic breeds and their hybrids are found to be at higher risk. This might go together with better producers and intensive management [19]. Most breeds of goats are fully prone to *B. melitensis*. There's great variation within the susceptibility of various breeds of sheep, where Malta sheep are very resistant, whereas fat-tailed sheep are very susceptible [85]. Brucella is an intracellular bacterium, hence their protection from the innate hosts defense and therapeutics, and moreover, during a very dormant state, it doesn't cause the formation of humoral antibodies [87].

The PH of the environment: The Brucella organism is sensitive to direct sunlight, disinfectants, and pasteurization. Brucella may retain infectivity for several months and survive for up to 4 months in milk, urine, water, and damp soil under proper environmental conditions [85, 88]. Disinfectants like hydrated oxide, formalin 2%, Lysol 1%, hypochlorite solutions, and 70% ethanol destroy Brucella. They're going to even be destroyed by moist heat at 121°C (250°F) for a minimum of a quarter-hour, dry heat of 320-338°F (160-170°C) for a minimum of 1 hour, gamma irradiation, and pasteurization. Boiling for 10 minutes is often effective for liquids [88].

Husbandry systems have a significant impact on the spread of infection. Lambing within dark, crowded enclosures is more favorable for spreading the disease than lambing within

an open environment. The most considerable risk factor for introducing the disease into a previously non-infected area is the purchase of infected animals. In several countries, there's a strong correlation between the prevalence of brucellosis in small ruminants and the practice of transhumance [89].

The reservoir hosts livestock like cattle, goats, sheep, pigs, camels, buffalo, and dogs [90]. The organisms reside inside cells of the immune system and reproductive tract and cause lifelong, chronic infections [91]. Carrier animals facilitate the transmission of brucellosis by contaminating the environment and also serving as the site of multiplication for the Brucella organisms in their bodies and excreting the agents. The execrable organisms infect animals and humans, which then cause hazards to the health and economy of the country.

Carriers like dogs, cats, and wild carnivores like foxes and wolves, which may be important as mechanical disseminators of infection by carrying away infected material like fetuses or fetal membranes, enhance the viability of the organisms within the environment, thus increasing the prospect of infecting susceptible animals [51]. People who work with animals or are exposed to infected blood are more likely to contract brucellosis. In addition to veterinarians, dairy farmers, ranchers, hunters, microbiologists, and people handling artificial incrimination, abattoir and slaughterhouse personnel working in endemic areas are in danger and regarded as potential bioweapons [89, 92].

2.4. Pathogenesis and Clinical Sign

2.4.1. Pathogenesis

Following cell invasion, Brucella strains survive and multiply in both phagocytic and non-phagocytic cells. The main targets for this bacterium are macrophages, dendritic cells, and trophoblasts cells. However, Brucella can also multiply within other cells, such as murine fibroblast or epithelioid cells [93]. Bacteria can spread in a host through the lymph nodes and then translocate to the reproductive tract's preferred issues [94]. There, Brucella induces acute or chronic infection of the reproductive tract that leads to abortion or severe reproductive tract diseases [95]. *Brucella melitensis* can infect mammalian hosts by abrasions or scrapes on the skin, as well as the ocular, reproductive, respiratory, and gastrointestinal tracts. Brucella in phagosomes survives by reducing host cell apoptosis and decreasing phagosome-lysosome fusion. They multiply in vacuoles within the endoplasmic reticulum and visit a range of organs, including the liver, spleen, muscle, and therefore the urogenital tract, where they cause granulocytic inflammation with or without necrosis [92].

The Brucella organisms enter the placenta and eventually the fetus after spreading through the hematogenous pathway in females because of the provision of allantoic fluid components (erythritol, four-carbon alcohol) that will drive Brucella expansion, preferentially localized to the reproductive tract of pregnant animals. The Brucellae proliferate significantly within the chorioallantoic trophoblasts, which are a serious component of the placenta and are linked to abortion. The termination of the pregnancy is due to loss of placental integrity and fetal infection, which results in premature birth and infected lambs or kids [86]. Additionally, hormonal abnormalities in infected placentas may mark the occurrence of abortion, as an increase in prostaglandin, estrogen, and cortisol, as well as a decrease in progesterone, may affect the occurrence of abortion in infected placentas. The uterine infection can last up to five months after an abortion, and the duct gland can even be affected [96, 97].

2.4.2. Clinical Signs of Brucellosis in Sheep and Goats

The incubation period of brucellosis in animals varies markedly depending on the size of the infective dose, age, sex, stage of gestation, and immunity of the affected animals [96]. Infection of the reproductive tract and abortions are the most common clinical symptoms of brucellosis in sheep and goats. On the other hand, cattle and goats may remain infected during their entire lives, in which case they suffer from chronic brucellosis. Moreover, they can transmit the disease to other animals and may be an important source of human infection through their milk and meat products [98].

Abortion occurs in cattle after the fifth month of pregnancy, while it occurs in the last two months of pregnancy in sheep and goats. Most animals do not miscarry in the second and subsequent pregnancies [98, 99]. In subsequent pregnancies, the uterus is invaded again, and organisms are shed together with the membranes and fluids [96]. Retained placenta, metritis, hygroma, orchitis, epididymitis, decreased milk production, permanent or temporary infertility, delay in reproductive seasons, and increased lactation intervals can be cited as other symptoms of this disease. In all sexes, severe lymphadenitis involving the retropharyngeal and inguinal lymph node is often present, although other lymph nodes may be affected [98]. The incubation period might range from 15 days to months or even years [100]. It's possible that excretion within the vaginal fluid and urine will remain for 4-6 months, and non-pregnant sheep and goats are asymptomatic [30]. The necrotic cotyledons become thicker and dull-grey in color, losing their blood-red look. The epididymis grew four or five times its size during the chronic stage of the disease. These lesions don't seem to be Brucellosis pathognomonic [101]. Dogs can become infected by swallowing aborted fetuses and/or placental material and infect humans and domestic livestock [13].

In humans, *B. melitensis* and B. suis are known to be extremely dangerous [51]. Brucellosis causes intense fevers, sweats, headaches, and flu-like symptoms in people [48, 102]. Because of the shortage of erythritol within the human placenta and fetus, it is widely assumed that brucellosis causes fewer spontaneous miscarriages than it does in animals. Anti-Brucella action has also been found in human humor [86].

2.5. Economic Significance of Small Ruminant Brucellosis

Brucellosis in sheep and goats could be a zoonotic infection that has significant public health, animal health, and production effects. Detaining seropositive animals in

quarantine has a negative economic impact because small ruminants and their products could be valuable export items. The main economic effects of brucellosis are the loss of animal genetic resources; death in lambs and kids; outbreak investigation; vaccine and research costs; movement restrictions; culling of infected animals; and export loss due to the risk of infected meat, milk, and by-products. Abortion, stillbirth or weak lambs or kids, loss of production, and infertility are all results of reproductive losses [103]. Brucellosis is usually a disease of animals, with people functioning as intentional hosts [58].

The expansion of animal industries, poor hygienic farming systems, inappropriate food processing, and consumption of raw milk and by-products have all contributed to the persistence of brucellosis as a public health problem. *Brucella melitensis*, Brucella abortus, and Brucella suis are the most common causes of brucellosis in humans. Since there's close contact between humans and their livestock, which sometimes share identical housing enclosures, there's a significant health risk to the whole community [13]. People at high risk include slaughterhouse workers, hunters, farmers, veterinarians, and laboratory personnel [51]. Infected herds' milking intervals are lengthened as a result of sterility, and therefore the average inter-calving duration could be extended by several months. Infection-related production losses, preventative measures, and, within the case of humans, treatment expenditures and absenteeism from work all entail a variety of economic implications [78].

2.6. Diagnostic Methods of Brucellosis in Small Ruminants

2.6.1. Direct Microscopic Examination

Modified Ziehl-Neelsen staining will be used to stain placental cotyledon smears, discharge, or fetal stomach contents. Brucellae aren't acid-fast organism, but they are resistant against decolorization by weak acids and stain red [104]. They seem like gram-negative coccobacilli or short rods; this can lead to a presumptive brucellosis diagnosis (Mizak et al., 2014). Infectious agents like Chlamydia species and Coxiella burnetii, on the other hand, have a superficial resemblance to Brucella [51].

The impression smears will be done by firmly pressing the slide surface on the tissue from freshly sliced and blotted tissue surfaces. The smears were dried on air before being fixed with heat. After staining with Modified-Ziehl-Neelsen, the bacteria appear as red intracellular coccobacilli, whereas most other bacteria stain blue [104]. However, other organisms that induce abortions, morphologically related bacteria, can confuse the diagnosis [45]. Because there are fewer Brucella in milk and dairy products, direct microscopic approaches have low sensitivity. The presence of fat globules can often make interpretation difficult. Culture and polymerase chain reaction (PCR) procedures will be employed to verify the results, whether positive or negative [105].

2.6.2. Bacterial Isolation and Identification

Bacterial isolation is the gold standard diagnostic approach for brucellosis because it's specific and allows biotyping of the isolate, which is vital in terms of epidemiology [106]. The Brucella organism should only be handled in level three laboratories; it's one of the most prevalent lab-acquired illnesses, especially in research labs [107]. The selection of samples for diagnosing animal brucellosis by culture investigation is principally supported by the clinical signs observed. Vaginal secretions (swabs), aborted fetuses (stomach contents, spleen, and lung), fetal membranes, milk, semen, the testis or epididymis, and infected joints and hygroma fluids are among the most important samples. At necropsy, the spleen, various lymph nodes (supramammary and vaginal lymph nodes), the pregnant or early post-parturient uterus, the udder, and therefore the male sex organ are additionally recommended. Growth appears in 3–4 days on average, although cultures shouldn't be discarded as negative until 10–20 days have passed [15].

A vaginal swab may be an excellent source of Brucella recovery following an abortion or parturition, and it is significantly less harmful to the person [15]. Suspected samples were immediately transported to the diagnostic laboratory for isolation [108]. The swab is then streaked immediately onto selective solid media and a pool of milk samples from all four mammary glands [45]. Isolation of Brucella spp. from vaginal swabs, sperm, and seminal fluid is more challenging because there are few live organisms, and contamination of clinical samples leads to false-negative results [109].

Brucella spp. may be a fastidious bacterium that demands plenty of nutrients so as to grow. Additionally, it requires an outsized number of viable bacteria in clinical samples, adequate storage, good laboratory facilities, and personnel training so as to undertake the technique safely. On selective medium, a blood agar base with 5% sterile sero-negative equine or bovine serum is added. To inhibit the growth of contaminants, nutrient-rich media supplemented with antibiotics (Polymixin B 5,000 UI/L; bacitracin 25,000 UI/L; cyclohexamide 100 mg/L; nalidixic acid 5 mg/L; nystatin 100,000 UI/L and vancomycin 20 mg/L) were used. In some circumstances, an enrichment medium with specific antibiotics can boost sensitivity [110].

2.6.3. Inoculation of Laboratory Animals

Unless absolutely required, laboratory animals mustn't be used. However, in other cases, it should be the sole way to detect Brucella, particularly when samples are extensively contaminated or likely to contain a small number of Brucella organisms [15]. Mice are reported to be the most commonly utilized animal model in brucellosis studies [111]. Guinea pigs are reported to be vulnerable and may be used. Suspected tissue homogenates of 0.5–1 ml were given intramuscularly or subcutaneously, and samples were tested and guinea pigs were sacrificed three to six weeks following inoculation [112]. In mice, inoculation is through the gastrointestinal tract or the nose (aerosol) [30]. Mice spleens are cultured seven days after inoculation. Gastric acid, on the other hand, has been shown to interfere with Brucella infectivity in experimental animals [111].

2.6.4. Molecular Methods

The PCR, which incorporates a real-time format, adds to the detection and identification of Brucella spp. [105]. Despite the high degree of DNA homology within the genus Brucella, numerous molecular approaches have been developed, like PCR, fragment length polymorphism (RFLP), and Southern blot, that allow the excellence of Brucella species and certain of their biovars to some extent. Differentiation of assorted Brucella species has been achieved using pulse-field gel electrophoresis. Although PCR may successfully identify Brucella species and differentiate vaccine strains, there has been minimal validation of PCR for direct diagnosis [113].

For Brucella identification and typing, molecular biological approaches, often supported by polymerase chain reaction (PCR) amplification, are successfully utilized to bypass the challenges of bacteriological testing [114]. DNA isolation from biological samples could be a critical step in PCR-based procedures, and its quality has a major impact on the method's sensitivity [115]. PCR-based identification was originally developed to work out bacterial isolates [116]. However, these approaches are now also utilized to detect Brucella species in animal clinical samples and humans [115].

PCR utilizing one set of primers specific to bacterial DNA sequences, like the 16S-23S rRNA operon, IS711, or BCSP31 genes, is the easiest and most reliable method of Brucella identification [117]. It's feasible to spot the four Brucella species: *Brucella melitensis*, Brucella abortus, Brucella suis, and Brucella canis employing a combination of primer pairs for amplification of BCSP31, OMP2B, OMP2A, and OMP31 genes encoding external membrane proteins [118]. The technique's overall performance can be determined by the DNA extraction protocol, the type of clinical sample used, and the detection limits of each protocol [119]. Due to the numerous risks of laboratory-acquired infections, routine identification and classification of brucellosis suspected specimens, supported culture isolation and phenotypic characterization necessitate biosafety level-3 (BSL-3) techniques [120].

Real-time PCR is a variety of PCR that's faster and more sensitive than traditional PCR [121]. The power to quantify DNA copy number and mRNA expression levels, similarly to the quick identification and discrimination of Brucella species, has made Real-Time PCR an appealing and accessible technology [122]. Real-time PCR appears to be extremely repeatable, fast, sensitive, specific, and straightforward to standardize, and therefore the danger of infection among laboratory personnel is low. There's no need to examine PCR products using agarose gel electrophoresis and no need to handle PCR products after amplification, minimizing the danger of laboratory contamination and false-positive results [123]. Using fluorescence resonance energy transfer, three distinct real-time PCRs were created to uniquely detect seven biovars of B. abortus, three biovars of *B. melitensis*, and one biovar of B. suis [123].

The upstream primers for these real-time PCRs came from the IS711 insertion element, while the reverse primer and FRET probes came from distinct species or biovar-specific chromosomal locations [124]. *B. abortus*-specific assays had sensitivity to 0.25 pg DNA, which corresponded to 16–25 genome copies, and *B. melitensis* and B. suis-specific assays had similar detection values. These assays target the 16S-23S ITS region, the IS711 element, and therefore the genes omp25, omp31, and bcsp31 [125]. The bcsp31 gene target may be a good choice for genus-level identification of bacteria. It's possible to validate the initial diagnosis by employing a second gene target, like IS711, to spot the species [126].

The first species-specific multiplex PCR technique for the differentiation of Brucella was described by Bricker [127]. The AMOS-PCR assay supported a polymorphism resulting from species-specific localization of the insertion sequence IS711 within the Brucella chromosome, and it included five oligonucleotide primers that would identify B. abortus biovars 1, 2, and 4 without distinguishing them, but not biovars 3, 5, 6, or 9. The assay has been modified over time to boost performance, and extra strain-specific primers for identifying B. abortus vaccine strains, as well as other biovars and species, have been added [128]. For quick and straightforward one-step identification of Brucella, a completely unique multiplex PCR test (Bruce-ladder) has been developed [129]. The biggest advantage of this assay over previously documented PCR is that it can identify and discriminate most Brucella species, including the vaccine strains B. abortus S19, B. abortus RB51, and *B. melitensis* Rev.1, during a single step [129].

The first species-specific multiplex PCR assay for the differentiation of Brucella was described by [127]. The assay, named AMOS-PCR based on a polymorphism resulting from species-specific localization of the insertion sequence IS711 within the Brucella chromosome, and it included five oligonucleotide primers that would identify B. abortus biovars 1, 2, and 4 without distinguishing them, but not biovars 3, 5, 6, or 9. The assay has been modified over time to boost performance, and extra strain-specific primers for identifying B. abortus vaccine strains, as well as other biovars and species, have been added [128]. For quick and straightforward one-step identification of Brucella, a unique multiplex PCR test (Bruce-ladder) has been developed [129].

The biggest advantage of this assay over previously documented PCR is that it can identify and discriminate most Brucella species, including the vaccine strains B. abortus S19, B. abortus RB51, and *B. melitensis* Rev.1, in an exceedingly single step. This novel PCR assay distinguishes between all currently recognized Brucella species, including the recently described species B. pinnipedialis (formerly named 'B. maris' or 'B. pinnipediae'), B. ceti (formerly named 'B. maris' or 'B. pinnipediae'), and B. microti, including some more recently described strains of the latter species [31, 130].

Immunohistochemistry could be a technique that may be used to diagnose Brucella species infection. It's been widely employed in investigations of brucellosis development and diagnostics, with in-place localizations of organisms within Brucella-induced lesions [101]. This method has the advantage of not requiring live microorganisms and allowing

retrospective analyses [131]. Although immunohistochemistry is easy, various parameters, like the fixation process and first antibody selection, can influence the result [132].

2.6.5. Serological Test

The Rose Bengal agglutination test (RBAT) may be a fast test with low sensitivity and specificity [133]. The Rose Bengal plate test could be a serum-based rapid slide-type test. The agglutination of blood antibodies against smooth lipopolysaccharide is the general principle of those tests. Inactivated B. abortus entire cells were dyed with Rose Bengal dye and buffered at pH 3.65 to forestall nonspecific agglutinins. It's the most commonly used test for brucellosis screening, especially in laboratories with limited resources, because of its simplicity and cheap cost [134].

The Rose Bengal Agglutination test results were interpreted to support the degree of agglutination and got the numbers 0, +, ++, and +++. A score of 0 indicates no agglutination; + indicates agglutinations that are scarcely visible; ++ indicates fine agglutination; and +++ shows coarse clumping. Agglutination with +, ++, and +++ is taken into account as positive [88]. The Rose Bengal agglutination test has low sensitivity, especially in chronic instances, and low specificity in endemic areas, likewise as prozone effects, which cause strongly positive sera to appear negative within the Rose Bengal Test, especially in animals exposed to brucella or having a history of infection [135]. The World Health Organization (WHO) recommended further assays like CFT should be done to confirm the Rose Bengal Test due to cross reaction [136, 137].

The complement fixation test detects IgM and IgG1 antibodies with excellent accuracy and fixes complement. It's employed as a confirmatory test for B. abortus, *B. melitensis*, and *B. ovis* infections and is therefore the OIE's approved reference test for international animal transit [30]. The CET has two-step reactions; the primary step is that the antigen, complement, and serum are mixed and incubated at 37°C for half an hour, then the indicator system is added and incubated. The complement fixation test has a high cost, a high level of execution complexity, and also requires specialized equipment and laboratory employees. The CFT has drawbacks with hemolysed serum, anti-complement activity, and also the presences of prozone events [104, 138] describe a sensitivity range of 77.1 to 100% and a specificity range of 65 to 100%. Because CFT captures more IgG1 antibodies than IgM antibodies, and since IgG1 antibodies normally emerge after IgM antibodies, CFT is the ideal tool for brucellosis control and surveillance [139].

The slow agglutination tube test (SAT) is the earliest serological test for the diagnosis of brucellosis, supported by bacterial antigen agglutination, notably by IgM under neutral pH. It's the most precise and preferred method of diagnosis, with a high specificity of 100.0 percent and an occasional sensitivity of 95.6 percent [140]. It counts the full number of IgM and IgG agglutinating antibodies. Treatment of the serum with 0.05M 2-mercaptoethanol (2ME), which inactivates the agglutinability of IgM, determines the number of particular IgG. Cross-reactivity of the Brucella smooth lipopolysaccharide antigen with other gram-negative bacteria raises the danger of false-positive results [104]. In both acute and chronic occurrences of brucellosis, the enzyme linked immunosorbent assay (ELISA) is more sensitive, providing a significant diagnostic advantage in endemic areas. The mixture of ELISA IgM and IgG tests should be utilized for identification and proper diagnosis of suspected cases. The presence of antibodies against the smooth lipopolysaccharide is employed to diagnose brucellosis [141].

The enzyme-linked immunosorbent assay (ELISA) could be a great tool for screening large groups of individuals and animals for Brucella antibodies [51]. It is the go-to test for complex, localized, or chronic cases, especially when other tests return negative and there are plenty of clinical suspicions. It can detect total and individual-specific immunoglobulin (IgG, IgA, and IgM) within 4-6 hours and has high sensitivity and specificity. In Addition to immunoglobulin classes, ELISA may detect Brucella-specific IgG subclasses and other Brucella immunoglobulin-like IgE, unlike typical agglutination methods [142].

The indirect ELISA method is based on antibodies present in the test sample binding specifically to immobilize antigen. Chemically or enzymatically produced fluorescent, luminescent, or colorimetric reactions are used to visualize the binding event. There are numerous I-ELISA tests on the market [45]. The indirect ELISA (I-ELISA) has been utilized for the serologic diagnosis of brucellosis in cattle, sheep, goats, and pigs. It's also been used to make diagnoses with cow's milk [143]. Indirect ELISA is commonly used for smooth LPS Brucella spp., and it is sensitive and specific for B. abortus or *B. melitensis*, but it cannot distinguish antibodies generated by vaccine strains S19 or Rev1 [144]. I-ELISA has a sensitivity range of 96 to 100 percent and a specificity range of 93.8 percent to 100 percent [145].

In a competitive ELISA, samples are premixed with a specific monoclonal antibody (Mab) in a preplate before being transferred to a coated microplate. The monoclonal antibodies (mAbs) have slightly lower affinity than the antibodies arising from the infection [146]. The specificity of c-ELISA is incredibly high and it's capable of identifying all antibody isotopes (IgM, IgG1, IgG2, and IgA) [104]. A competitive ELISA (c-ELISA) coated plate with smooth Brucella LPS was developed because the antigen can detect Brucella antibodies in serum samples from cattle, sheep, goats, and pigs. This test can distinguish between vaccination antibody responses and real illnesses, with sensitivity starting from 92 to 100 percent and specificity between 90 and 99 percent [116].

The milk ring test (MRT) is employed to screen herds for brucellosis in lactating animals. The sensitivity of the test becomes less reliable in large herds greater than 100 lactating cows). To account for the dilution of bulk milk samples from large herds, the MRT is adjusted. The following formula is employed to switch the samples: For herds of fewer than 150 animals, a 1 mL bulk milk sample is employed; a 2 mL milk sample is used for herds of 150–450 animals, and a 3 mL milk sample is employed for herds of 451–700 animals. False-

positive reactions can occur in calves who are vaccinated but 4 months before being tested, in samples that contain unusual milk (such as colostrum), or in cases of mastitis. As a result, using this test on extremely small farms, where these issues have the greatest influence, isn't recommended [30].

Brucellin allergic diagnostic test: The skin test employs a protein antigen derived from Brucella or brucellergene or brucellin [116]. Because Brucellosis can cause cellular and antibody-mediated responses within the host, the Brucellin diagnostic test should be employed in cases of false-positive serological reactions. Skin tests have a high specificity; latently infected animals without detectable antibodies, as well as unvaccinated animals that test positive, should be considered infected [113]. As a consequence, the results of this test may help interpret serological reactions that are assumed to be false-positive because of infection with cross-reacting bacteria, particularly in brucellosis-free locations [147].

The test requires injecting brucellin into the flank or intrapalpebrally, then measuring the thickness of the skin [148]. All infected animals that don't react to the present test mustn't be used as a sole diagnostic tool or for international trade (OIE, 2009). Similarly, post-vaccination, the test's specificity is lowered, and also the requirement for 2 farm visits, the time between repeat tests, and therefore the subjective nature of result interpretation render this sort of test impracticable for accurate diagnosis [149].

The gamma interferon assay for in-vitro detection of cell-mediated immunity (lymphocyte transformation and proliferation) revealed insufficient efficacy to be used for routine Brucella infection diagnosis on a broad scale [47]. The identification of the involvement of certain cytokines, like interferon (IFN) gamma, in protection against intracellular agents has allowed the creation of an in-vitro test with diagnostic applications within the previous decade. In the interferon-gamma release assay, lymphocytes in the blood are stimulated with an appropriate antigen, like brucellin. A capture ELISA is employed to detect the following gamma-interferon (IFN) production [15].

2.7. Public Health Importance of Brucellosis

The World Health Organization lists Brucellosis, often referred to as Gibraltar fever, Malta fever, or Bang's sickness, among other names, as a neglected zoonotic disease [85]. In endemic countries, *B. melitensis* infects humans through consumption of unpasteurized milk and by-products or through direct contact with contaminated discharge materials, aborted fetuses, and incisions within the skin, inhalation, or mucous membranes, being the most common cause. Diseased animals which might shed an outsized number of bacteria after abortion [150].

Farmers, veterinarians, inseminators, and laboratory personnel are in danger of developing Brucellosis because it's an occupational disease. People are less likely to guard themselves while handling fetal fluids and vaginal discharges following abortion or full-term parturition. Furthermore, like other diseases, poor individuals, particularly in rural areas, are less likely to receive effective diagnosis and treatment, and since brucellosis is zoonotic, it's a double burden in poor homes, affecting both people and their animals [85].

Human brucellosis appears as an acute or sub-acute sickness with intermittent or relapsing fever, ague, malaise, sweating, muscle pain, anorexia, and prostration in the early stages. The acute phase may progress to a chronic incapacitating phase characterized by persistent localized infection, like osteoarticular problems, or the more general "chronic fatigue syndrome." Human brucellosis is often misdiagnosed as drug-resistant malaria in tropical areas, and it's under-detected and thus under-reported in most regions of the globe [85, 13]. Despite the fact that human mortality is kind of low, this crippling, chronic characteristic of the disease is especially distressing in rural communities that lack proper health care and where good physical condition for work is required [151].



Figure 2. *Shows zoonotic Brucella spp. transmited from animal to humans.*

2.8. Treatment, Prevention and Control

2.8.1. Treatment of Brucellosis

Antibiotics that penetrate macrophages and are active in an acidic environment are required for an efficient brucellosis treatment to be implemented [152]. The treatment of Brucellosis necessitates the administration of antibiotics in large doses at regular intervals. Many studies have shown that antibiotics must be used for a minimum of six weeks or longer to avoid recurrence or resistance [153]. During the first 2-3 weeks, researchers discovered that a double and triple antibiotic regimen using aminoglycosides like streptomycin or gentamicin was effective. Treatment of animals isn't frequent in developing nations; rather, diseased animals are culled and isolated, or slaughtered to stop infection from spreading to the remainder of the herd and to save lots of money on veterinary expenses. Thanks to the high treatment failure rate, cost, and potential complications related to retaining sick animals in the face of on-going eradication attempts, treating infected animals isn't recommended [154].

In China, antibiotic therapy (ceftriaxone, doxycycline, rifapentine) was helpful in treating a difficult Brucella infection case with subdural emphysema and intracerebral abscess [155]. In line with this, multiple studies have demonstrated that a six-week course of doxycycline and rifampicin is sufficient to eradicate Brucella infection and its consequences [156, 157]. Due to the scientific community's ongoing attempts to make effective medicines, Caryopterismongolica bunge (Lamiaceae) has been tried together with doxycycline and rifampicin [97, 158, 159]. Despite the fact that there are various treatments in use to keep the disease manageable, effective therapy is important for total brucellosis treatment (Khan et al., 2018). In the treatment of brucellosis, alternative antibiotics or chemotherapeutics like fluoroquinolones or co-trimoxazole with rifampicin, doxycycline-streptomycin, and doxycycline-rifampicin are being employed [160].

2.8.2. Prevention and Control

In contrast to treatment, prevention is far easier, safer, and less expensive. As a result, while managing infections, especially zoonotic diseases like Brucellosis, prevention is critical. When a veterinarian encounters or suspects brucellosis, they ought to follow their national and/or local disease reporting criteria. Infected animals are the most likely source of *B. melitensis* in a herd. Contact with possibly infected animals or contaminated materials, like those animals that have recently been aborted, should be avoided in *B. melitensis*-free herds. Replacement stock should come from Brucella-free herds; newcomers should be isolated and tested before being allowed into the herd. Some infected animals, particularly those latently infected while they were young, were undetectable by serology or culture. Only Brucella-negative animals' sperm should be taken for insemination, and it should be examined on a regular basis [15].

Contaminated bedding, aborted placenta, and any abortion products should all be removed and destroyed as soon as possible in an infected herd, and contaminating fomites should be cleaned [15]. Fitting a chosen lambing or kidding space makes it easier to wash and disinfect the area in between deliveries. Through testing and slaughter, likewise as depopulation, movement limits on infected herds, surveillance and monitoring of infected animals, and programs to eradicate this pathogen from a country. Dogs are vulnerable to illness. Several countries compel shepherd dogs to be destroyed or castrated after being treated with antibiotics [15, 30]. Pasteurizing milk, eating processed meat, frequent checkups and immunizations of animals, as well as maintaining health safety when working with infected animals and in laboratories, are all methods used to avoid brucellosis infection [153].

2.9. Vaccination

There are currently no effective human vaccines available, while various Brucella vaccines are available for livestock. Vaccination is one of the most effective techniques for preventing and controlling livestock brucellosis. *B. melitensis* Rev-1, B. abortus strain RB51, B. abortus S-19, *B. melitensis* strain M111, B. suis S-2 are available in various parts of the world. *B. melitensis* H. 38 and B. abortus 45/20 are dead vaccines used commonly. Vaccination virtually eliminates brucellosis clinical signs and symptoms while also reducing environmental contamination and population exposure to the infectious agent [53].

The REV 1 vaccine is an attenuated strain of *B. melitensis* that will be used to prevent brucellosis in whole flocks or herds in endemic countries [100]. This strategy, however, proved difficult in many areas where the animals were housed in large settings with nomadic or semi-nomadic husbandry, and it didn't lessen the disease's frequency or incidence. Herd immunity takes an extended time to work out. Furthermore, mature animals who haven't been vaccinated are defenseless, and thus the infection might spread. Vaccination of all animals in an exceedingly flock (young and adults) is an alternate method of brucellosis control in small ruminants. Where there's an outsized incidence of diseased animals, bulk immunization is usually recommended [30]. Mass vaccination of a flock accelerates the establishment of comparable immune stock and reduces the quantity of abortions and excretions, lowering environmental contamination and disease transmission [53].

For cattle Brucellosis control, the RB51 attenuated live vaccine has lately acquired prominence. Despite extensive investigation, no vaccine for the prevention of human brucellosis has been authorized. The treatment of human brucellosis requires the utilization of a mix of medicines. Vaccination is sometimes advised for seroprevalence rates of two to 10% in animals. This could be appropriate for farms when combined with good hygienic practices, but in large-scale livestock situations, vaccination is additionally required to manage the disease [161]. Subunit vaccines, like recombinant proteins, are potential vaccine candidates

because they're less biohazardous, clearly defined, avirulent, non-infectious, and nonviable than whole vaccinations [162].

3. Conclusion

Brucellosis is a zoonotic infectious disease. It is considered one of the neglected diseases that do not have enough awareness like other infectious diseases. This review is focused on Brucellosis since it is an endemic disease in the land of patoral areas of Ethiopia. High prevalence rate (17.36%) and low prevalence rate (0.7%) was reported in Ethiopia [61, 10] respectively. It's thought to be a typical animal disease and causes economic losses to the livestock industry. Brucellosis also affects fertility and is banned from the international trade of live animals and animal products. Goats and sheep are the principal hosts for *B. melitensis* and *B. ovis*, respectively, with *B. melitensis* playing a major role in human infection [14, 15].

People work with domestic animals, veterinarians, abattoir employees, laboratory professionals, and inseminators are among the people at high occupational risk. They're endangered by direct contact with infected animals or exposure to a highly contaminated environment. Additionally, people become infected by ingesting unpasteurized milk and by-products [12, 15]. As a result, suitable control techniques to limit brucellosis in infected and reservoir animals are essential. In Ethiopia, epidemiological surveillance of diseases, including isolation of causative agents and characterization, may be a critical effort, particularly in endemic lowland areas. Awareness creation among those who work with animals, further knowledge of brucellosis for those involved in milk production, handling of abortive materials and disposal, and culling of infected animals from herds. One health approach, between human and veterinary medicine, aims at improving community health.

Conflict of Interests

The authors declare that they have no competing interests.

References

[1] Gebremedhin B., Hoekstra D., Tegegne A., Shiferaw K. and Bogale A. (2015): Factors determining house hold market participation in small ruminant production in the high land of Ethiopia. International livestock Research Institute (ILRI), Addis Ababa Ethiopia.

[2] Tedeschi L. O., Nicholson C. F. and Rich E. (2011): Using system dynamics modeling approach to develop management tools for animal production with emphasis on small ruminants. *Small Ruminant Research,* 98: 102-110.

[3] Gobena M. M. (2016). Review on Small Ruminant Production, Marketing and Constraints in Ethiopia. *Advances in Life Sci. and Tech.*, (48): 28-34.

[4] Zahra A., Mulema A., Colverson K., Odongo D. and Rischkowsky B. (2014): A review of Ethiopia Small ruminant value chains from a gender Perspective. Nairobi: *ILRI* and *ICARDA*. pp 1-38.

[5] CSA. 2020a. Agricultural Sample Survey 2019/20 [2012 E. C.]. Volume II report on livestock and livestock characteristics (private peasant holdings). Central Statistical Agency (CSA): Addis Ababa, Ethiopia.

[6] CSA (2017). Agricultural sample survey 2016/2017 volume I report on area and production of major crops.

[7] Mustefa M, Bedore B. (2019) Review on epidemiology and economic impact of small ruminant brucellosis in Ethiopian perspective. *Vet Med Open J*.; 4 (1): 77-86.

[8] Biffa, Demelash, Yilma Jobre, and Hassen Chakka. "Ovine helminthosis, a major health constraint to productivity of sheep in Ethiopia." *Animal Health Research Reviews* 7, no. 1-2 (2006): 107-118.

[9] Muma JB., Samui L., Oloya J., Munyeme M. and Skjerve E. (2007): Risk factors for brucellosis in indigenous cattle reared in livestock-wildlife interface areas of Zambia. *Prev Vet Med.,* 80: 306-317.

[10] Tewodros, A. E. and Dawit, A. A., 2015. Sero-Prevalence of Small Ruminant Brucellosis in and around Kombolcha, Amhara Regional State, North-Eastern Ethiopia. *J Vet Sci Med Diagn 4*, *5*, p. 2.

[11] Ethiopia's Livestock Systems (2021): Overview and Areas of Inquiry. Gainesville, FL, USA: Feed the Future Innovation Lab for Livestock Systems.

[12] WHO. (2012). Brucellosis. Geneva (Switzerland): World Health Organization. www.who.int/zoonoses/diseases/brucellosis/en/.

[13] Corbel M. J. (2006). Brucellosis in humans and animals. The World Health Organization, in collaboration with the Food and Agriculture Organization of the United Nations and the World Organization for Animal Health (WHO) Geneva.

[14] Awah-Ndukum J., Mouiche M. M. M., Bayang H. N., NguNgwa N., Assana E., Feussom K. J. M., Manchang T. K. and Zoli P. A. (2018): Seroprevalence and Associated Risk Factors of Brucellosis among Indigenous Cattle in the Adamawa and North Regions of 26. Ehizibolo DD., Gusi AM., Ehizibolo PO., Mbuk EV. and Ocholi, R. A. (2011): Serologic Prevalence of Brucellosis in Horse Stables in Two Northern States of Nigeria. *Journal of Equine Science*., 22 (1): 17-1.

[15] OIE (2018). Manuals of Diagnostic Tests and Vaccine for Tesrrestrial Animals. Office International des Epizooties (OIE). Paris, (France).

[16] Moreno E. (2014). Retrospective and prospective perspectives on zoonotic brucellosis. *Frontiers in microbiology*, *5*, 213. https://doi.org/10.3389/fmicb.2014.00213

[17] El-Wahab EWA, Hegazy Y, Wael F, Mikael A, Kapaby AF, Abdelfatah M, Bruce M, Eltholth MM. (2019). Knowledge, attitudes and practices (KAPs) and risk factors of brucellosis at the human-animal interface in the Nile Delta, Egypt. BioRxiv.607655.

[18] Megid J., Mathias Lab. and Robles CA. (2010): Clinical manifestations of Brucellosis in domestic animals and humans. *Vet Sci J.* 4: 119–26.

[19] Rossetti CA., Arenas AM. and Maurizio E. (2017): Caprine brucellosis: a historically neglected disease with significant impact on public health. *PLoS Negl Trop Dis*., 11: 56–92.

[20] Seleem, Mohamed N., Stephen M. Boyle, and Nammalwar Sriranganathan. "Brucellosis: a re-emerging zoonosis." *Veterinary microbiology* 140, no. 3-4 (2010): 392-398.

[21] Kelkay M. Z., Gugsa G., Hagos Y. and Taddelle H. (2017): Sero-prevalence and associated risk factors for Brucella sero-positivity among small ruminants in Tselemti districts, Northern Ethiopia. *J. Vet Med and Ani Heal.*, 9 (11); 320-326.

[22] Hirsh, D. C., Maclachlan N. J. and Walker R. (2004): Veterinary Microbiology. Black well science USA 105-112.

[23] Khan M. Z and Zahoor M. (2018): An Overview of Brucellosis in Cattle and Humans, and its serological and molecular Diagnosis in control strategies. *Trop. med. Dis*., 3: 65.

[24] Whatmore AM. (2009). Current understanding of the genetic diversity of Brucella, an expanding genus of zoonotic pathogens. *Infect Genet Evol*. 9 (6): 1168-84. Doi: 10.1016/j.meegid. PMID: 19628055.

[25] Santellano-Estrada E., Infante F., Diaz-Aparicio, E. and Flores-Guetierrez G. H. (2004): Use of an immune binding test on nitrocellulose paper to diagnose caprine brucellosis *Vet. Res. Commun*, 28 (1): 27-31.

[26] Ehizibolo DD., Gusi AM., Ehizibolo PO., Mbuk EV. and Ocholi, R. A. (2011): Serologic Prevalence of Brucellosis in Horse Stables in Two Northern States of Nigeria. *Journal of Equine Science*., 22 (1): 17-19.

[27] Galińska E. M. and Zagórski J. (2013). Brucellosis in humans-etiology, diagnostics, clinical forms. *Ann. Agric. Environ. Med*., 20 (2): 233–238.

[28] Whatmore A. M., Davison N., Cloeckaert A., Dahouk S Al., Zygmunt M. S., Brew S. D., Perrett L. L., Koylass M. S., Vergnaud G., Quance C. and others. (2014): *Brucella papionis* sp. nov., isolated from baboons (*Papio* spp.). *Int. J. Syst. Evol. Microbiol.,* 64 (12): 4120–4128. doi: 10.1099.

[29] Scholz H. C., Nockler K., Gollner C., Bahn P., Vergnaud G., Tomaso H., AL Dahouk S., KampferP., Cloeckaert A., Maquart M. and Zygmunt M. S. (2016): Serological and Molecular Diagnosis in Control Strategies. *Trop. Med. Infect. Dis*., 3: 65.

[30] OIE (2009). Bovine Brucellosis; caprine and ovine brucellosis and porcine brucellosis. In: World assembly of delegates of the Paris: Office International des Epizooties (OIE) Terrestrial Manual. Chapter 2.4.3. Paris, France. pp. 1–35.

[31] Scholz HC., Hofer E., Vergnaud G., Le Fleche P. and Whatmore AM. (2009): Isolation of *Brucella microti* from mandibular lymph nodes of red foxes, Vulpes, in lower Austria. *Vector Borne Zoonotic Dis.,* 9: 153-156.

[32] DE Jong M. F. and Tsolis R. M. (2012): Brucellosis and type IV secretion. *Future Microbiol*, 7 (1): 47-58.

[33] Winchell J. M., Wolff B. J., Tiller R., and Bowen M. D. and Hoff master A. R. (2010): Rapid identification and discrimination of brucella isolates by use of Real-time PCR and High-Resolution Melt Analysis. *J Clin Microbiol.,* 48 (3): 697–702.

[34] Mizak L., R Gryko., Parasion S. and Kwiatek M. (2014): Brucellosis – *a worldwide zoonosis (in Polish). Życ. Wet,* 89 (1): 35–40.

[35] Negash E., Shimelis S. and Beyene D. (2012): Seroprevalence of small ruminant brucellosis and its public health awareness in selected sites of Dire Dawa region, Eastern Ethiopia. *J Vet Med Animal Health.*, 4: 61-66.

[36] CSA (2014). Federal Democratic Republic of Ethiopia, Central Statistical Agency, Agricultural sample survey 2013/14 (2006 E. C). Vol II. Report on livestock and livestock characteristics (Private Peasant Holdings). Statistical Bull. PP. 573.

[37] CSA (2005). Estimated Number of Cattle, Sheep and Goats by Regions. Central Statistics Authority (CSA), Addis Ababa.

[38] Pappas G., Papadimitriou P., Akritidis N., Christou L. and Tsianos E. (2006): The new global map of human brucellosis. *Lancet Infect Dis*., 6: 91-9.

[39] Godfroid J, Cloeckaert A, Liautard JP. (2005): From the discovery of the Malta fever's agent to the discovery of a marine reservoir, brucellosis has continuous been a re-emerging zoonosis. *Vet Res* 36: 313-26.

[40] Xavier M. N., Costa E. A., Paixao T. A. and Santos R. L. (2009a): Genus *Brucella* and clinical manifestations. *Ciência Rural*., 39 (7): 2252-2260.

[41] FAO (2003). Guidelines for coordinated human and animal brucellosis surveillance. *Animal Production and Health Paper* 156: 2.

[42] Lapaque N., Moriyon I., Moreno E. and Gorvel J. P. (2005): *Brucella* lipopolysaccharide acts as a virulence factor. *Curr Opin Microbiol,* 8 (1): 60–66.

[43] Godfroid J., Al Dahouk S., Pappas G., Roth F., Matope G., Muma J., Marcotty T., Pfeiffer D. and Skjerve E. (2013): A "One Health" surveillance and control of brucellosis in developing countries: Moving away from improvisation. Comp. *Immunol. Microbial. Infect. Dis*., 36 (3): 241-248.

[44] KO KY., Kim JW., Her M., Kang SI. and Jung SC. (2012): Immunogenic proteins of Brucella abortus to minimize cross reactions in brucellosis diagnosis. *Vet Microbiol,* 156: 374-380.

[45] Poester P. P., K. Nielsen., Samartino L. E. and Yu W. L. (2010): "Diagnosis of Brucellosis. *Open Vet Sci J*. 4: 46-60.

[46] Dabassa G., Tefera M. and Addis M. (2013): Small Ruminant Brucellosis: Serological Survey in Yabello District, Ethiopia. *Asian J Anim Sci.,* 7: 14-21.

[47] European Commission (2001). Brucellosis in Sheep and Goat (*Brucella Melitensis*). In: Report of the scientific committee on animal health and animal welfare of the Europian Commission.

[48] Franco M. P., Mulder M., Gilman H. R. and Smits, L. H. (2007): Human brucellosis. *Lancet Infect Dis.,* 7: 775-786.

[49] Barua A., Kumar A., Thavaswlvam D., Mangalgi S., Prakash A., Tiwari S. and Sathyaseelan K. (2016): Isolation and Characterization of *Brucella melitensis* isolated from patient suspected for human brucellosis in India. *Indian journal of medical research,* 143 (5): 652.

[50] Russo A. M., Mancebo O. A., Monzon C. M., Gait J. J., Casco R. D. and Torion S. M. (2016): Epidemolgy de la brucellosis caprina y ovina en la provincial de Formosa, Argentina. *Revista Argentina de micribilogy*., 48 (2): 147-153.

[51] Gall D., Nielsen K., Vigliocco A., Smith P. and Perez B. (2003): Evaluation of an indirect-linked immunoassay for presumptive serodiagnosis of *Brucella ovis* in sheep. *Small Rum Res*., 48: 173-179.

[52] Banai M. (2007). Control of *Brucella melitensis*. Memorias del IV Foro Nacional de Brucelosis, Facultad de Medicina Veterinariay Zootecnia de la Universidad Nacional Autónoma de México (FMVZ-UNAM), 26–27 November, Mexico, DF.

[53] OIE (2012). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 7th ED. Office International des Epizooties (OIE). Paris, France. Office International des Epizooties (OIE). Paris, (France).

[54] Blasco J M and Molina-Flores B. (2011). Control and eradication of *Brucella melitensis* infection in sheep and goats. *Veterinary Clinics of North America (Food Animal Practice)* 27 (1): 95–104.

[55] Memish Z. A and Balkhy H. H. (2004): Brucellosis and international travel. *J Travel Med.,* 11: 49–55.

[56] Garin-Bastuji B., Mick V and Carrou G. Le (2014): Examination of taxonomic uncertainties surrounding *Brucella abortus* bv. 7 by phenotypic and molecular approaches," *Applied and Environmental Microbiology*, 80 (5): 1570–1579.

[57] Garry A. L. and Christopher J. S. (2010). Natural resistance against brucellosis. *Open Vet Sci J*. 4: 61-71.

[58] Regassa G. (2017). Brucellosis and its control through one health approaches Ethiopia. *J. Vet Med*., 4 (3): 1080.

[59] MOA, ILRI, 2013. Dairy value chain vision and strategy for Ethiopia. Addis Ababa, Ethiopia: Ministry of Agriculture and International Livestock Research Institute.

[60] Tesfaye, A., Dejene, H., Admasu, B., Kassegn, T. A., Asfaw, D., Dagnaw, G. G., & Bitew, A. B. 2021. Seroprevalence of Bovine Brucellosis in Ethiopia: Systematic Review and Meta-Analysis. Veterinary medicine (Auckland, N. Z.), 12, 1–6.

[61] Dereje Teshome, Teshale Sori, Taferi Banti, Getachew Kinfe, Barbara Wieland, Gezahegn Alemayehu (2022). Prevalence and risk factors of *Brucella spp*. in goats in Borana pastoral area, Southern Oromia, Ethiopia.

[62] Tekle M., Legesse M., Mammo B. Edao., Ameni G. and Mamo G. (2019): Isolation and identification of *Brucella melitensis* using bacteriological and molecular tools from aborted goats in the Afar region of north-eastern Ethiopia. *Biomed Central Microbiology*., 19 (1): 108.

[63] Sintayehu G., Melesse B., Abayneh D., Sintayehu A., Melaku S., Alehegne W., Mesfin M., De Blas I., Casal J., Allepuz A; Martin-Valls G., Africa A. and. Abera A. (2015): Epidemiological survey of brucellosis in sheep and goats in selected pastoral and agro-pastoral lowlands of Ethiopia. *Rev. Sci. Tech. Off. Int. Epiz.,* 34 (3), 881-893.

[64] Tadeg W. M., Gudeta F. R., Mekonen T. Y., Asfaw Y. T., Birru A. L. and Reda A. A. (2015): Seroprevalence of small ruminant brucellosis and its effect on reproduction at Tallalak district of Afar region, Ethiopia. *J. Vet. Med. Anim. Health.,* 7 (4): 111-116.

[65] Tegegn AH., Feleke A., Adugna W. and Melaku SK. (2016): Small Ruminant Brucellosis and Public Health Awareness in Two Districts of Afar Region, Ethiopia. *J Veterinar Sci Technol.,* 7: 335. doi: 10.4172/2157-7579.1000335.

[66] Wubishet Z. (2020). Study on sero-prevalence of small ruminant and human brucellosis in Yabello and dire districts of Borena zone Oromia regional state, Ethiopia. *American J. Anim and Vet Sci*., 15: (1): 26. 31.

[67] Edao BM., Ameni G., Assefa Z., Berg S., Whatmore AM. and Wood JLN (2020): Brucellosis in ruminants and pastoralists in Borena, Southern Ethiopia. *PLoS Negl Trop Dis.,* 14 (7): e0008461. https://doi.org/10.1371/journal.pntd.0008461.

[68] Geremew H., Abu T and Lijalem N. (2018): A sero-Prevalence of Small Ruminant Brucellosis in Selected Settlements of Dire Dawa Administrative Council Area, Eastern Ethiopia. *Arcjournals.org.,* 3 *(2)*: PP 7-14.

[69] Lemma S., Leza A., Gercha G, and Radii A. (2019): Sero prevalence study of brucellosis in goats in hamer and BenaTsemay Woreda's of south omo, Ethiopia. *International Journal of Research - Granthaalayah*, 7 (8), 166-174. https://doi.org/10.5281/zenodo.3381116

[70] Mohammed M., Mindaye S., Hailemariam Z., Tamerat N. and Muktar Y. (2017): Sero-Prevalence of Small Ruminant Brucellosis in Three Selected Districts of Somali Region, Eastern Ethiopia. *J Vet Sci Anim Husb.,* 5 (1): 105. Doi: 10.15744/2348-9790.5.105.

[71] Teferi B. (2021). Msc thesis on serological, isolation and molecular detection of brucellosis in small ruminants in selected pastoral districts of oromia and Somali regional states, (Ethiopia).

[72] Geletu, Umer Seid, Munera Ahmednur Usmael, and Yesihak Yusuf Mummed. "Seroprevalence and risk factors of small ruminant brucellosis in West Hararghe Zone of Oromia Regional State, Eastern Ethiopia." *Veterinary Medicine International* 2021 (2021).

[73] Yeshibelay, G., and Teferi, A., 2019. Sero-Prevalence of Caprine Brucellosis in BabileWoreda, Eastern Hararghe, Ethiopia. *J. Dairy. Vet. Sci.,* 10 (3): ID. 555789.

[74] Aliyi Adem, Adem Hiko, Hika Waktole3, Fufa Abunna3, Gobena Ameni, Gezahegne Mamo (2020). Small ruminant *brucella* sero-prevalence and potential risk factor at dallo-manna and haranna-bulluk districts of bale zone, oromia regional state, Ethiopia. ethiop, vet., 25, (1) 77-95.

[75] Dereje tulu; Abiy gojam and Benti Deresa (2020*).* Serological investigation of brucellosis and its association with abortion in sheep and goats in selected districts of Jimma zone, southwestern Ethiopia. *Ethiop. vet. j., 2020, 24 (1), 15-33.*

[76] Glenn J., Songer and Karen W. Post. (2005). Veterinary Microbiology: Bacterial and Fungal agents of animal diseases; pp-200-203.

[77] Bauerfeind R., Graevenitz A. and Kimmig P. (2016): *Zoonoses: Infectious Diseases Transmissible from Animals and Humans*. Washington, DC, USA: ASM Press; 192-195.

[78] Gul, T and Khan A. (2007): Epidemiology and epizootology of brucellosis. *Pakistan Vet J*. 27 (3): 145-151.

[79] Ashenafi F., Teshale S., Ejeta G., Fikru R. and Laikemariam Y. (2007): Distribution of brucellosis among small ruminants in pastoral region of a far, Eastern Ethiopia. *Rev Sci Tech*., 26 (3): 731-739.

[80] Franc K. A., Krecek R. C., Häsler B. N. and Arenas-Gamboa A. M. (2018): Brucellosis remains a neglected disease in the developing world: a call for interdisciplinary action. *BMC Public Health,* 18: 125.

[81] Grilló MJ; Blasco JM; Gorvel JP; Moriyón I and Moreno, E. (2012). What have we learned from brucellosis in the mouse model. *Vet. Res*., 43: 1-35.

[82] Hegazy YM., Moad A., Osman S., Ridler A. and Guitian J. (2011): Ruminant Brucellosis in the kafr el-sheikh governate of the Nile delta, Egypt prevalence of neglected Zoonosis. *Plos Negl Trop Dis*., 5 (1): e944.

[83] Gadaga B. (2013). A survey of brucellosis and bovine tuberculosis in humans at a wildlife/ domestic animal/human interface in Zimbabwe. Research platform Production and conservation in partnership (RP-PCP). pp 5.

[84] Center for Food Security and Public Health (2012) – www.cfsph.iastate.edu

[85] WHO (2006). The control of neglected zoonotic diseases: a route to poverty alleviation: report of a joint WHO/DFID-AHP meeting, 20 and 21 September 2005. World Health Organization (WHO), Geneva.

[86] Hotez P. J., Savioli, L., and Fenwick, A. (2012): Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. *PLoS Negl Trop Dis.*, 6 (2), e1475.

[87] Guven G., Lozano-Sanchez P. and Guven A. (2013): Power generation from human leukocytes/lymphocytes in mammalian biofuel cell. *International Journal of Electrochemistry.,* 1-11. Doi: 10.1155/2013/706792.

[88] Radostitis O. M., Gay C., Blood D. C. and Hinchclift K. W. (2007): Veterinary Medicine: a text book of the Disease of cattle, sheep, pigs, goats and horse. *Harcourt publishers limited*, London. pp. 882-885.

[89] Kanani A, Dabhi S, Patel Y, Chandra V, Vinodh Kumar OR, Shome R (2018). Seroprevalence of brucellosis in small ruminants in organized and unorganized sectors of Gujarat state, India, *Veterinary World*, 11 (8): 1030-1036.

[90] Moreno E., Cloeckaert A. and Moriyoni I. (2002): *Brucella* evolution and taxonomy. *Vet*. *Microbiol*, 90: 209–227.

[91] PAHO (2001). Zoonoses and Communicable diseases common to man and animals. Pan American Health Organization (PAHO).3rd Edition; V-1; Washington D. C., USA. pp 53-55.

[92] Alemu Y. and Markel R. C. (2008): Sheep and goat production hand book for Ethiopia. Web *site. http://www.igadhost.com/igaddata/docs/Sheep%20and%20Goat %20,* Production %20 Hand%20 Book%20 for%20, ETHIOPIA.

[93] Xavier M. N., T. A. Paixao, A. B. den Hartigh, R. M. Tsolis and R. L. Santos. 2010. Pathogenesis of *Brucella* spp. *Op. Vet. Sci. J.* 4: 109–118.

[94] Kim S. 2015. The interaction between *Brucella* and the host cell in phagocytosis, pp. 45–60. In: Baddour M. (ed.). *Updates on Brucellosis.*

[95] He Y. 2012. Analyses of Brucella pathogenesis, host immunity, and vaccine targets using systems biology and bioinformatics. *Front. Cell. Infect. Microbiol.* 2: 2. doi: 10.3389/fcimb.2012.00002.

[96] Ashraf M A., Ahmed K A., Torad F A. and Marouf S A. (2015): Ultrasonographic and histopathological findings in rams with epididymo-orchitis caused by *Brucella melitensis.pvj.com.pk.,* 35 (4): 456-460.

[97] Saxena H. M. and Raj S. (2018): A novel immunotherapy of Brucellosis in cows monitored non-invasively through a specific biomarker. *PLoS Negl. Trop. Dis.,* 12: e0006393.

[98] Wanke, M. M., 2004. Canine brucellosis. *Animal Reproduction Science 82-83, 195-207.*

[99] Greiner M, Verloo D. and de Massis F. (2009): Meta-analytical equivalence studies on diagnostic tests for bovine brucellosis allowing assessment of a test against a group of comparative tests. *Prev Vet Med*., 92: 373–81.

[100] FAO (2010). *Brucella melitensis* in Eurasia and the Middle East. Food and Agriculture Organization of the United Nations (FAO), Animal Production and Health Proceedings. No. 10 Rome.

[101] Xavier M. N., Paixao T. A., Poester F. P., Lage A. P. and Santos R. L. (2009b): Pathology, immunohistochemistry and bacteriology of tissues and milk of cows and fetuses experimentally infected with *Brucella abortus*. *Journal of Comparative Pathology*, 140: 149-157.

[102] Nigatu S., Deneke M. and Kassa T. (2014): Sero-prevalence of Brucellosis in sheep and goat destined for slaughter in selected export abattoirs, Ethiopia. *African J. Basic & Appl Sci.,* 6 (3): 82-86.

[103] Quinn, P. J., Carter, M. E., Markey, B. K., Carter, G. R., 2004. Brucella species, Bacteriology, Clinical Veterinary Microbiology, Dublin, Pp 261–267.

[104] Nielsen K., Gall D., Smith P., Balsevicius S. and Garrido F. (2004): Comparison of serological tests for the detection of ovine and caprine antibody to *Brucella melitensis. Rev Sci Tech.,* 23: 979-987.

[105] Bricker BJ. (2002). Diagnostic strategies used for the identification of Brucella. *Vet Microbiol,* 90: 433-434.

[106] Dahouk, S. A., Neubauer, H., Hensel, A., Schoneberg, I., Nockler, K., Alpers, K., Merzenich, H., Stark, K., Jansen, A., 2007. Changing epidemiology of human brucellosis, Germany, 1962–2005. Emerg. Infect. Dis. 13, 1895–1900.

[107] Sam IC., Karunakaran R., Kamarulzaman A., Ponnampalavanar S. and Syed Omar SF. (2012): A large exposure to *Brucella melitensis* in a Diagnostic laboratory. *Hosp Infect.,* 80: 321-325.

[108] Nielsen H. and Ewalt R. (2004): Bovine brucellosis: In manual of standards for diagnostic tests and vaccines, (5th Edn) OIE, Paris, France, pp: 328-345.

[109] Hadush A. and Pal M. (2013): Brucellosis, An infectious re-emerging bacterial zoonosis of global importance. *Int J Livestock Res.,* 3 (1): 28-34. doi: 10.5455/ijlr.20130305064802.

[110] DE Miguel M. J., Marin C. M., Munoz P. M., Dieste L., Grillo M. J. and Blasco J. M. (2011): Development of a selective culture medium for primary isolation of the main *Brucella* species. *J. Clin. Microbiol,* 49, 1458–1463.

[111] Silva TM A., Costa EA, Paixao TA., Tsolis RM. and Santos RL. (2011). Laboratory Animal Models for Brucellosis Research. *J. Biomed. Biotechnology*. Article ID 518323, 9 pages.

[112] OIE (2009a). Ovine and Caprine Brucellosis: *B. melitensis* Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. World Organization for Animal Health (OIE). Paris, France. pp1344.

[113] Whatmore a. m. & Gopaul k. k. (2011). Recent advances in molecular approaches to *Brucella* diagnostics and epidemiology. *In: Brucella*: Molecular Microbiology and Genomics, López-Goñi I. & O'Callaghan D., eds, Caister Academic Press, Norfolk, UK, 57–88.

[114] Yu W. L. and K. Nielsen, (2010): "Review of Detection of *Brucella* spp. by Polymerase Chain Reaction," *Croat Med J*. 51 (4): 306-313.

[115] Dauphin LA., Hutchins RJ., Bost LA, and Bowen MD. (2009): Evaluation of Automated and Manual Commercial DNA Extraction Methods for Recovery of *Brucella* DNA from Suspensions and Spiked Swabs. *J Clin Microbiol.,* 47 (12): 3920–3926.

[116] Le Flèche P., Jacques I., Grayon M., Al Dahouk S. and Bouchon P. (2006): Evaluation and selection of tandem repeat loci for a Brucella MLVA typing assay. *BMC Microbiol,* 6: 9.

[117] Godfroid J., Nielsen K. and Saegerman C. (2010): Diagnosis of brucellosis in livestock and wildlife. *Croat Med J.,* 51: 296-305.

[118] Imaoka K., Kimura M., Suzuki M., Kamiyama T. and Yamada A. (2007): Simultaneous Detection of the Genus *Brucella* by Combinatorial PCR," *Japanese Journal of Infectious Diseases,* 60: 2-3, 137-139.

[119] Mitka S., Anetakis C., Souliou E., Diza E. and Kansouzidou A. (2007): Evaluation of different PCR assays for early detection of acute and relapsing brucellosis in humans in comparison with conventional methods. *J Clin Microbiol.,* 45: 1211-1218.

[120] Boschiroli ML., Ouahrani-Bettache S. and Foulongne V. (2002): Type IV secretion and *Brucella* virulence. *Vet Microbiol*, 90: 341–348.

[121] Alarcon BB., Vicedo and R. Aznar. (2006): "PCR-Based Procedures for Detection of *Staphylococcus aureus* and Their Application in Food. *J Appl Microbiol.,* 100: 352–364.

[122] Ginzinger DG. (2002). Gene quantification using real-time quantitative PCR: *an emerging technology hits the mainstream. Exp. Hematol*., 30: 503–512.

[123] Wang Y., Wang Z. and Zhang Y. (2014): Polymerase chain reaction-based assays for the diagnosis of human brucellosis. *Ann Clin Microbiol Antimicrob.,* 13: 31.

[124] Redkar R., Rose S., Bricker B. and DelVecchio V. (2001): Real-time detection of *Brucella abortus*, *Brucella melitensis* and Brucella Suis. *Mol Cell Probes*, 15: 43-52.

[125] Zhang B., Wear DJ., Stojadinovic A. and Izadjoo M. (2013): Sequential real-time PCR assays applied to identification of genomic signatures in *brucella*-induced osteomyelitis. *Mil Med*., 178 (1): 88–94.

[126] Colmenero JD., Clavijo E., and Morata P., Bravo MJ. and Queipo-Ortuño MI. (2011): Quantitative real-time polymerase chain reaction improves conventional microbiological diagnosis in an outbreak of brucellosis due to ingestion of unpasteurized goat cheese. *Diagn Microbiol Infect Dis*., 71 (3): 294–6.

[127] Halling S. M., Peterson-Burch B. D. and Bricker BJ. (2005): Completion of the genome sequence of *Brucella abortus* and comparison of the highly similar genomes of *Brucella melitensis* and *Brucella Suis. J. Bacteriol*., 187: 2715–2726.

[128] Ocampo-Sosa A. A., Balbin J. A. and Garcia-Loboi J. M. (2005): Development of a new PCR assay to identify *Brucella abortus* biovars 5, 6 and 9 the new subgroup 3b of biovar 3. *Vet Microbiol,* 110: 41-51.

[129] Garcıa-Yoldi D., Marın CM., de Miguel MJ., Munoz PM. and Vizmanos JL. (2006): Multiplex PCR assay for the identification and differentiation of all *Brucella* species and the vaccine strains *Brucella abortus* S19 and RB51 and *Brucella melitensis* Rev1. *Clin Chem*., *52*: 779–781.

[130] Huber B., Scholz HC., Lucero N. and Busse HJ. (2009): Development of a PCR assay for typing and sub typing of *Brucella* species. *Int J Med Microbiol,* 299: 563-573.

[131] Santos RL., Xavier MN., Paixao TA., Poster FP. and Lag AP. (2009). Pathological, immunohistochemical and bacteriolgical study of tissues and milk of cows and fetuses experimentally infected with *Brucella abortus*. Jornal of comparative pathology 140 (2-3): 149-157.

[132] Ramos-Vara J. A. (2005). Technical aspects of immunohisto chemistry. *Veterinary Pathology*, 42: (4) 405-426.

[133] Ezama A., Gonzalez J-P., Majalija S. and Bajunirwe F. (2018): Assessing short evolution brucellosis in a highly *brucella* endemic cattle keeping the population of Western Uganda: a complementary use of Rose Bengal test and IgM rapid diagnostic test. *BMC Public Health.,* 18: 315.

[134] Mantur B. G., Birada, M. S., Bidri, R. C., Mulimani, M. S. and Kariholu, P. (2006): Protean Clinical manifestations and Diagnostic Challenges of Human Brucellosis in Adults: 16 years' experience in an endemic area. *J. Med Microbiol,* 55: 897-903.

[135] Díaz R., Casanova A., Ariza J. and Moriyón I. (2011): The Rose Bengal Test in human brucellosis: a neglected test for the diagnosis of a neglected disease. *PLoS Negl Trop Dis.,* 5 (4): e950.

[136] Araj GF, (2010). Update on laboratory diagnosis of human brucellosis. *Int J Antimicrob Agents*. 36S: S12-7.

[137] Sathyanarayan S., Suresh S., Krishna S. and Mariraj J. (2011): A comparative study of agglutination tests, blood culture and ELISA in the laboratory diagnosis of human brucellosis. *Int J Biol Med Res.,* 2: 569-572.

[138] Perrett, L. L., McGiven, J. A., Brew, S. D. and Stack, J. A. (2010): Evaluation of competitive ELISA for detection of antibodies to Brucella infection in domestic animals. *Croat med J. 51* (4): 314-319.

[139] OIE, (2016). Brucellosis Infection; Adopted by the World Assembly of Delegates of the Office International des Epizooties (OIE). Paris, France. 2: 1-14.

[140] Elham E. (2018). Pediatric brucellosis: An update review for the new millennium. *Saudi Med J.* 39: 336-341.

[141] Mantur B., Parande A., Amarnath S., Patil G. and Walvekar R. (2010): ELISA versus conventional methods of diagnosing endemic brucellosis. *Am J Trop Med Hyg,* 83: 314-318.

[142] Agasthya S., Isloor S. and Krishnamsetty P. (2012): Seroprevalence study of human brucellosis by conventional tests and indigenous indirect enzyme linked immunosorbent assay. *Sci World J.* 1: 1-3.

[143] Di Febo, T; Luciani, M.; Portanti, O.; Bonfini, B.; Lelli, R.; Tittarelli, M. Development and evaluation of diagnostic tests for the serological diagnosis of brucellosis in swine. Veterinaria Italiana, v. 48, n. 2, p. 145-156, 2012.

[144] Lim JJ., Kim DH., Lee JJ., Kim DG, and Min W. (2012): Evaluation of recombinant 28 kDa outer membrane protein of *Brucella abortus* for the clinical diagnosis of bovine brucellosis in Korea. *J Vet Med Sci.,* 74: 687-691.

[145] Gall D. and Nielsen K. (2004): Serological diagnosis of bovine brucellosis: a review of test performance and cost comparison. *Rev Sci Tech.,* 23: 989-1002.

[146] Munoz PM, Marin CM, Monreal D, et al. Efficacy of several serological tests and antigens for diagnosis of bovine brucellosis in the presence of false-positive serological results due to *Yersinia enterocolitica O: 9*. *Clin Diagn Lab Immunol*. 2005; 12 (1): 141–151. doi: 10.1128/CDLI.12.1.141-151.200564.

[147] De Massis F., Giovannini A., Di Emidio B., Ronchi GF., Tittarelli M., Di Ventura M., Nannini D. and Caporale V. (2005): Use of the complement fixation and brucellin skin tests to identify cattle vaccinated with *Brucella abortus* strain RB51. *Vet. Ital.,* 41 (4): 291-29.

[148] Cheville NF. Jensen AE., Morfitt DV and, Stabel TJ. (1994): Cutaneous Delayed Hypersensitivity Reactions of Cattle Vaccinated with Mutant Strains of *Brucella abortus*, using Brucellins Prepared from Various *Brucella* Strains. Am. *J. Vet. Res.* 55 (19): 1261-1266.

[149] Cutler SJ., Whatmore AM. and Commander NJ. (2005): Brucellosis new aspects of an old disease. A *Review. J. Appl. Microb*., 98: 1270-1281.

[150] Ahuja V., Rajabova R., Ward D. and McLeod A. (2009): Willingness to pay for disease prevention: Case of brucellosis control in Khatlon Oblast of Tajikistan. Food and Agriculture Organization of the United Nations (FAO). WHO, with the participation of FAO and OIE. http://www.who.int/zoonoses/Report

[151] Jackson R., Ward D., Kennard R., Amirbekov M., Stack J., Amanfu W., El-Idrissi A. and Otto H. (2007): Survey of the seroprevalence of brucellosis in ruminants in Tajikistan.

[152] Ranjbar M. 2015. Treatment of brucellosis, pp. 171-184. In: Baddour M. (ed.). *Updates on Brucellosis*. InTech, Teheran.

[153] Srivastava A. and Singh H. (2011): Brucellosis: Its diagnosis, prevention and treatment. *J Chem Pharm*., 912-917.

[154] Yousefi-Nooraie R., Mortaz-Hejri S., Mehrani M. and Sadeghipour P. (2012): Antibiotics for treating human brucellosis. *Cochrane Database Syst. Rev*., 10, Cd007179.

[155] Zhang J., Chen Z., Xie L., Zhao C., Zhao H., Fu C., Chen G., Hao Z., Wang L. and Li W. (2017): Treatment of a subdural empyema complicated by intracerebral abscess due to *Brucella* infection. *Braz. J. Med. Biol. Res*., 50, e5712.

[156] Meng F., Pan X. and Tong W. (2018): Rifampicin versus streptomycin for brucellosis treatment in humans: A meta-analysis of randomized controlled trials. *PLoS One.*, 13: e0191993.

[157] Kaya S., Elaldi N., Deveci O., Eskazan E. A., Bekcibasi M. and Hosoglu S. (2018): Cytopenia in adult Brucellosis patients. *Indian J. Med. Res.*, 147, 73-80.

[158] Yang H. X., Feng J. J., Zhang X. Q., Hao E. R., Yao X. S., Zhao R., Piao R. D., Cui Y. B. and Jiang H. (2018): A case report of spontaneous abortion caused by *Brucella melitensis* biovar 3. *Infect. Dis. Poverty*., 7: 31.

[159] Tsevelmaa N., Narangerel B., Odgerel O., Dariimaa D. and Batkhuu, J. (2018): Anti-Brucella activity of Caryopterismongolica Bunge root extract against *Brucella melitensis* infection in mice. *BMC Complement. Altern. Med*. 18: 144.

[160] Skalsky K., Yahav D., Bishara J., Pitlik S., Leibovici L and Paul M. (2008): Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. *BMJ*, 336 (7646): 701–704.

[161] Marzetti S., Carranza C., Roncallo M., Escobar G. I. and Lucero N. E. (2013): Recent Trends in Human *Brucella canis* infection. *Comparative Immunology, Microbiology and Infectious Disease,* 36: 55–61.

[162] Pasquevich K. A., Ibañez A. E. and Coria L. M. (2011): An Oral Vaccine Based on UOmp19 Induces Protection against *B. Abortus* Mucosal Challenge by inducing an Adaptive IL-17 immune response in mice.